Slovenja - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer europe ma eeig - etinilestradiol; gestoden - obložena tableta - etinilestradiol 20 µg / 1 tableta  gestoden75 µg / 1 tableta; gestoden 75 µg / 1 tableta - gestoden in etinilestradiol

Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

dechra regulatory b.v. - desoksikorton pivalat - kortikosteroidi za sistemsko uporabo - psi - za uporabo kot nadomestno zdravljenje za mineralocorticoid pomanjkljivost pri psih s primarno hypoadrenocorticism (addison bolezen).

Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatične neoplazme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Slovenja - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - medroksiprogesteronacetat - tableta - medroksiprogesteronacetat 100 mg / 1 tableta - medroksiprogesteron

Slovenja - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - medroksiprogesteronacetat - tableta - medroksiprogesteronacetat 500 mg / 1 tableta - medroksiprogesteron

Slovenja - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva b.v. - fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant

Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - neoplazme dojke - endokrini terapije, anti-estrogene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. v pre - ali perimenopausal ženske, kombinacija zdravljenja z palbociclib je treba v kombinaciji z luteinizirajoči hormon sproščujoči hormon (lhrh) agonist.

Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

novo nordisk a/s - somapacitan - rast - hipofize in hipotalamični hormoni in analogi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Slovenja - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant

Slovenja - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant